Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 
• By Sarah Karlin-Smith
  
Vinay Prasad
Vinay Prasad returns to lead CBER after a brief departure. (US FDA webstream)

More from US FDA

More from Cell & Gene Therapies